EUROPEAN PATIENT ADVOCACY GROUPS AWARDED GRANTS FROM POSITIVE ACTION EUROPE
13 May 2015, London UK: ViiV Healthcare announces today the first round of organisations awarded grants through our Positive Action Europe programme. A total of £100,000 in grants has been awarded to seven patient advocacy groups in Europe:
- Associacao Positivo, Portugal
- Center for Life, Greece
- Czech AIDS Help Association, Czech Republic
- DIA LOGS, Latvia
- ISKORAK, Croatia
- National AIDS Trust, UK
- Q-Club, Serbia
ViiV Healthcare recognises the enormous significance of the community response to HIV/AIDS and is committed to seek out and build new partnerships and connections to help strengthen education, support services, local healthcare capacity and capabilities, and to reduce stigma and discrimination towards people living with HIV/AIDS. The selected community-based projects focus their efforts on patient empowerment and education, increasing testing for early diagnosis and addressing emotional and societal issues such as the psychological impact of HIV on individuals and their families to tackle stigma and discrimination, a key issue affecting people living with HIV across Europe.[i]
About Positive Action
Positive Action was created in 1992 as the first pharmaceutical company programme to support communities affected by HIV and AIDS. ViiV Healthcare is proud to continue the Positive Action programme and its valuable work with these communities. Positive Action works with those communities most vulnerable to HIV disease, including youth, girls and women, sex workers, gay men, men who have sex with men (MSM), transgender people, injecting drug users (IDU), the homeless and the incarcerated. Our projects range across education, prevention, care and treatment-related activity such as treatment literacy and community/clinical engagement.
For more information on our community partnerships visit:
|Sébastien Desprez (UK)
Rachel Jaikaran (UK)
|+44 7920 567 707
+44 7823 523 755
[i] UN AIDS 2014: Reduction of HIV-related stigma and discrimination, Guidance Note. Source: http://www.unaids.org/sites/default/files/media_asset/2014unaidsguidancenote_stigma_en.pdf
For our corporate press office, email: Rachel Jaikaran
OR call +44 7823 523 755
For US-specific media enquiries,email:firstname.lastname@example.org
OR call +1 919 605 4521
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.